Latest Hotspot

European Commission approves Ascendis Pharma's YORVIPATH® (palopegteriparatide) for treating chronic Hypoparathyroidism in adults

29 November 2023
3 min read

Ascendis Pharma A/S has disclosed that the EC has granted approval for the selling and distribution of YORVIPATH® (palopegteriparatide), which is used as a replacement therapy for adult patients suffering from long-term hypoparathyroidism. YORVIPATH is a prodrug of the parathyroid hormone and is to be taken once a day. Ascendis is set to launch YORVIPATH in the EU for the first time in January 2024, starting in Germany.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

"People living with chronic hypoparathyroidism often experience a range of health and quality of life challenges," explained Prof. Lorenz C. Hofbauer, Professor of Medicine, Geriatrics, and Endocrinology at Technical University of Dresden. “It's crucial that we develop new means of treating the root cause of this disease, rather than just its symptoms. These currently include oral calcium and active vitamin D, but these conventional therapies have their limitations and potential risks."

Following a positive assessment by the European Medicines Agency's Committee for Medicinal Products for Human Use on September 14, 2023, YORVIPATH has now been approved by the European Commission.

Jan Mikkelsen, CEO and President of Ascendis Pharma, discussed their journey in the development of YORVIPATH. “We centered our focus on fulfilling the needs of patients, basing our actions on scientific findings, which has allowed us to receive EU marketing authorization for YORVIPATH – a second approved TransCon product – in merely eight years, with plans to release it in Germany by January. Aware of the urgent requirement expressed by numerous patients and healthcare providers for innovative treatment options, we will strive to make YORVIPATH accessible on a broader scale.”

YORVIPATH (also known as TransCon PTH), a parathyroid hormone replacement therapy, will be marketed in the EU for the management of adults suffering from chronic hypoparathyroidism. Physicians or healthcare professionals experienced in diagnosing and treating hypoparathyroidism should supervise its initiation and ongoing use. TransCon PTH is under development for adults with hypoparathyroidism in the US, Japan, and elsewhere.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面, 文本

描述已自动生成

According to the data provided by the Synapse Database, As of November 28, 2023, there are 4 investigational drugs for the CaSR and PTH1R target, including 2 indications, 6 R&D institutions involved, with related clinical trials reaching 17, and as many as 67 patents.

Palopegteriparatide shows promise as a hormone drug targeting CaSR and PTH1R for the treatment of hypoparathyroidism. The fact that it has reached the NDA/BLA stage globally and Phase 3 in China suggests that it has undergone rigorous testing and has demonstrated positive results in clinical trials. The priority review and orphan drug designations further highlight the potential value of Palopegteriparatide in addressing the specific medical needs of patients with hypoparathyroidism.

图形用户界面, 文本, 网站

描述已自动生成

What are KRAS inhibitors and how do you quickly get the latest development progress?
What are KRAS inhibitors and how do you quickly get the latest development progress?
29 November 2023
The KRAS mutation, as a significant driving factor for non-small cell lung cancer, has long been a challenging type of mutation. However, the recent development and clinical application of various KRAS inhibitors have brought us new hope.
Read →
ProMIS Neurosciences begins Phase 1a trial, administering PMN310, a potential Alzheimer's treatment, to initial participants
Latest Hotspot
3 min read
ProMIS Neurosciences begins Phase 1a trial, administering PMN310, a potential Alzheimer's treatment, to initial participants
29 November 2023
ProMIS Neurosciences initiates Phase 1a clinical trial, injecting the first participants with PMN310, a potential Alzheimer’s Disease treatment.
Read →
Exploring Iptacopan's R&D successes and its clinical results at the 2023 ASH
Exploring Iptacopan's R&D successes and its clinical results at the 2023 ASH
29 November 2023
On 11 Dec 2023, the final phase III APPLY-PNH trial data after a 24-wk extension period in which all pts received iptacopan monotherapy will be reported in 2023 ASH.
Read →
Immix Biopharma's IND for CAR-T NXC-201 approved by FDA, enabling treatment for U.S. patients
Latest Hotspot
3 min read
Immix Biopharma's IND for CAR-T NXC-201 approved by FDA, enabling treatment for U.S. patients
29 November 2023
Immix Biopharma confirms IND application for CAR-T NXC-201 has been sanctioned by FDA, allowing treatment dosage for U.S. patients.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.